The FDA is set to redesign its Centers of Excellence in Regulatory Science and Innovation (CERSI) collaborations with universities, a move confirmed by the Department of Health and Human Services (HHS) to Endpoints News. This initiative, which has been pivotal in addressing complex public health challenges through external research, will undergo significant changes in its funding structure over the next year.
This reworking of the CERSI program comes at a time when the need for innovative regulatory science is more pressing than ever. By refining its partnerships with academic institutions, the FDA aims to enhance the quality and impact of research that informs regulatory decision-making. The implications of these changes could lead to more effective solutions for pressing health issues, ultimately benefiting both the pharmaceutical industry and public health.
Start your 7-day trial and see what the database can do →
